These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35987403)

  • 1. An analysis of published trials found that current use of pragmatic trial labels is uninformative.
    Taljaard M; Nicholls SG; Howie AH; Nix HP; Carroll K; Moon PM; Nightingale NM; Giraudeau B; Hey SP; Eldridge SM; Weijer C; Zwarenstein M
    J Clin Epidemiol; 2022 Nov; 151():113-121. PubMed ID: 35987403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems.
    Palmer JA; Mor V; Volandes AE; McCreedy E; Loomer L; Carter P; Dvorchak F; Mitchell SL
    Trials; 2018 Aug; 19(1):453. PubMed ID: 30134976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating pragmatic and implementation science randomized clinical trial approaches: a PRagmatic Explanatory Continuum Indicator Summary-2 (PRECIS-2) analysis.
    Zatzick D; Palinkas L; Chambers DA; Whiteside L; Moloney K; Engstrom A; Prater L; Russo J; Wang J; Abu K; Iles-Shih M; Bulger E
    Trials; 2023 Apr; 24(1):288. PubMed ID: 37085877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework.
    Sharma T; Qamar I; Zwarenstein M
    J Clin Epidemiol; 2022 Dec; 152():193-200. PubMed ID: 36265553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory.
    Johnson KE; Neta G; Dember LM; Coronado GD; Suls J; Chambers DA; Rundell S; Smith DH; Liu B; Taplin S; Stoney CM; Farrell MM; Glasgow RE
    Trials; 2016 Jan; 17():32. PubMed ID: 26772801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials.
    Dal-Ré R
    Eur J Clin Pharmacol; 2021 Apr; 77(4):539-546. PubMed ID: 33106910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An application of PRECIS-2 to evaluate trial design in a pilot cluster randomised controlled trial of a community-based smoking cessation intervention for women living in disadvantaged areas of Ireland.
    Darker C; Loudon K; O'Connell N; Castello S; Burke E; Vance J; Reynolds C; Buggy A; Dougall N; Williams P; Dobbie F; Bauld L; Hayes CB
    Pilot Feasibility Stud; 2022 Jan; 8(1):19. PubMed ID: 35078530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRECIS-2 analysis of pragmatic acupuncture trials: a systematic review.
    Lim J; Lee H; Kim YS
    BMC Complement Med Ther; 2024 May; 24(1):181. PubMed ID: 38702632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing provider-focused implementation trials with purpose and intent: introducing the PRECIS-2-PS tool.
    Norton WE; Loudon K; Chambers DA; Zwarenstein M
    Implement Sci; 2021 Jan; 16(1):7. PubMed ID: 33413489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.
    Lipman PD; Loudon K; Dluzak L; Moloney R; Messner D; Stoney CM
    Trials; 2017 Nov; 18(1):532. PubMed ID: 29126437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool.
    Dal-Ré R
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1093-1102. PubMed ID: 32447436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facing the Realities of Pragmatic Design Choices in Environmental Health Studies: Experiences from the Household Air Pollution Intervention Network Trial.
    Checkley W; Hossen S; Rosa G; Thompson LM; McCracken JP; Diaz-Artiga A; Balakrishnan K; Simkovich SM; Underhill LJ; Nicolaou L; Hartinger SM; Davila-Roman VG; Kirby MA; Clasen TF; Rosenthal J; Peel JL; On Behalf Of Household Air Pollution Intervention Network Hapin Investigators
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRECIS-2 for retrospective assessment of RCTs in systematic reviews.
    Zwarenstein M; Thorpe K; Treweek S; Loudon K
    J Clin Epidemiol; 2020 Oct; 126():202-206. PubMed ID: 32565215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PRECIS-2 tool has good interrater reliability and modest discriminant validity.
    Loudon K; Zwarenstein M; Sullivan FM; Donnan PT; Gágyor I; Hobbelen HJSM; Althabe F; Krishnan JA; Treweek S
    J Clin Epidemiol; 2017 Aug; 88():113-121. PubMed ID: 28603007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The PRECIS-2 tool: designing trials that are fit for purpose].
    Hu GP; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Feb; 39(2):222-226. PubMed ID: 29495210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
    Bratton DJ; Nunn AJ; Wojnarowska F; Kirtschig G; Sandell A; Williams HC
    Trials; 2012 Apr; 13():50. PubMed ID: 22540678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Informing real-world practice with real-world evidence: the value of PRECIS-2.
    Neta G; Johnson KE
    BMC Med; 2018 May; 16(1):76. PubMed ID: 29783964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How pragmatic are the randomised trials used in recommendations for control of glycosylated haemoglobin levels in type 2 diabetic patients in general practice: an application of the PRECIS II tool.
    Ettori-Ajasse I; Tatin E; Forbes G; Eldridge S; Dibao-Dina C
    Trials; 2020 Mar; 21(1):281. PubMed ID: 32188470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalizability of randomized controlled trials in primary health care: Applying the PRECIS-2 tool on published protocols.
    Papagiannopoulou E; Laiou E; Tatsi C; Dimakopoulos G; Ntzani EE; Siamopoulos K; Tatsioni A
    J Eval Clin Pract; 2023 Mar; 29(2):253-262. PubMed ID: 36072984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.